Jorge Mesquita - Johnson Johnson Chairman

JNJ Stock  USD 156.76  1.42  0.90%   

Chairman

Mr. Jorge S. Mesquita is the Executive Vice President, Worldwide Chairman, Consumer of the Company. Mr. Mesquita joined the Company in 2014 as Worldwide Chairman, Consumer. Prior to joining the Company, he served in various marketing and leadership capacities across Latin America, including roles in Oral Care and Beauty at The Procter Gamble Company from 1984 to 2013. In April 2016, Mr. Mesquita became a member of the Executive Committee and was promoted to Executive Vice President, Worldwide Chairman, Consumer. Mr. Mesquita plans to retire from the Company in March 2019. since 2016.
Age 56
Tenure 8 years
Address One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933
Phone732 524 0400
Webhttps://www.jnj.com

Johnson Johnson Management Efficiency

The company has Return on Asset of 0.0833 % which means that on every $100 spent on assets, it made $0.0833 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1831 %, implying that it generated $0.1831 on every 100 dollars invested. Johnson Johnson's management efficiency ratios could be used to measure how well Johnson Johnson manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is expected to hike to 0.26 this year. Return On Assets is expected to hike to 0.13 this year. At this time, Johnson Johnson's Total Current Liabilities is relatively stable compared to the past year. Liabilities And Stockholders Equity is expected to hike to about 175.9 B this year, although the value of Change To Liabilities is projected to rise to (962.5 M).
The company has 30.43 B in debt with debt to equity (D/E) ratio of 0.43, which is OK given its current industry classification. Johnson Johnson has a current ratio of 1.4, which is typical for the industry and considered as normal. Debt can assist Johnson Johnson until it has trouble settling it off, either with new capital or with free cash flow. So, Johnson Johnson's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Johnson Johnson sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Johnson to invest in growth at high rates of return. When we think about Johnson Johnson's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 7 records

CHAIRMAN Age

Giovanni Lettieri23Andme Holding Co
58
Mats Olsson23Andme Holding Co
63
Daniel BradburyEquillium
63
Vernon LoboEquillium
48
James CullenAgilent Technologies
72
Richard PilnikDiaMedica Therapeutics
56
Boon KohAgilent Technologies
70
Johnson Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company was founded in 1886 and is based in New Brunswick, New Jersey. Johnson Johnson operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 141700 people. Johnson Johnson (JNJ) is traded on New York Stock Exchange in USA. It is located in One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933 and employs 131,900 people. Johnson Johnson is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Johnson Johnson Leadership Team

Elected by the shareholders, the Johnson Johnson's board of directors comprises two types of representatives: Johnson Johnson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Johnson. The board's role is to monitor Johnson Johnson's management team and ensure that shareholders' interests are well served. Johnson Johnson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Johnson Johnson's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jorge Mesquita, Executive Vice President Worldwide Chairman - Consumer
Duane Arsdale, Treasurer
Mary Coleman, Independent Director
Michael Ullmann, VP, General Counsel and Member of Executive Committee
Jasmina Brooks, President Webster
Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals
Nadja West, Independent Director
Mark Larkins, Worldwide Secretary
Vanessa Broadhurst, Executive Vice President Global Corporate Affairs
Louise Mehrotra, Vice President Investor Relations
Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices
Ronald Williams, Independent Director
Tom Cavanaugh, Company Medicine
D Davis, Independent Director
Anne Mulcahy, Lead Independent Director
Ian Davis, Independent Director
Dominic Caruso, CFO, VP of Fin. and Member of Executive Committee
Mark Weinberger, Independent Director
A Washington, Independent Director
Dirk Brinckman, Chief Officer
Jennifer Doudna, Independent Director
Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. Committee
William Perez, Independent Director
Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer
Marillyn Hewson, Independent Director
Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals
Joseph CPA, Executive CFO
Michael Bodner, Global Recovery
Kathy Wengel, Executive Vice President Chief Global Supply Chain Officer
Mary Beckerle, Independent Director
Darius Adamczyk, Independent Director
Sandra Peterson, Group Worldwide Chairman and Member of Executive Committee
Scott Davis, Director
Hani Abouhalka, Company Digital
Ahmet Tezel, Group RD
Robert Decker, Controller Officer
Mathai Mammen, Executive Vice President Pharmaceuticals, R&D
Timothy Schmid, Executive MedTech
Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer
William Hait, Executive Vice President Chief External Innovation, Medical Safety, Global Public Health Officer
James Swanson, Executive Vice President, Chief Information Officer
Hubert Joly, Independent Director
Joseph Wolk, Chief Financial Officer, Executive Vice President
Thibaut Mongon, Executive Vice President, Worldwide Chairman, Consumer Health
Jessica Moore, Vice Relations
Paulus Stoffels, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive Committee
Mark McClellan, Independent Director
Charles Prince, Independent Director
Celine Martin, Group CSS
Eugene Washington, Independent Director
Elizabeth Forminard, Executive Counsel
Peter Fasolo, Chief Human Resource Officer, Executive Vice President
Guy MD, Group EMEA
Susan Lindquist, Independent Director

Johnson Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Johnson Johnson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Johnson Johnson Investors Sentiment

The influence of Johnson Johnson's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Johnson. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Johnson Johnson's public news can be used to forecast risks associated with an investment in Johnson. The trend in average sentiment can be used to explain how an investor holding Johnson can time the market purely based on public headlines and social activities around Johnson Johnson. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Johnson Johnson's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Johnson Johnson's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Johnson Johnson's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Johnson Johnson.

Johnson Johnson Implied Volatility

    
  21.02  
Johnson Johnson's implied volatility exposes the market's sentiment of Johnson Johnson stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Johnson Johnson's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Johnson Johnson stock will not fluctuate a lot when Johnson Johnson's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Johnson Johnson in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Johnson Johnson's short interest history, or implied volatility extrapolated from Johnson Johnson options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Johnson Johnson is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Johnson Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Johnson Johnson Stock. Highlighted below are key reports to facilitate an investment decision about Johnson Johnson Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Johnson Johnson. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Johnson Stock please use our How to buy in Johnson Stock guide.
You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Complementary Tools for Johnson Stock analysis

When running Johnson Johnson's price analysis, check to measure Johnson Johnson's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Johnson Johnson is operating at the current time. Most of Johnson Johnson's value examination focuses on studying past and present price action to predict the probability of Johnson Johnson's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Johnson Johnson's price. Additionally, you may evaluate how the addition of Johnson Johnson to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Is Johnson Johnson's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Johnson Johnson. If investors know Johnson will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Johnson Johnson listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.106
Dividend Share
4.7
Earnings Share
5.2
Revenue Per Share
33.613
Quarterly Revenue Growth
0.073
The market value of Johnson Johnson is measured differently than its book value, which is the value of Johnson that is recorded on the company's balance sheet. Investors also form their own opinion of Johnson Johnson's value that differs from its market value or its book value, called intrinsic value, which is Johnson Johnson's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Johnson Johnson's market value can be influenced by many factors that don't directly affect Johnson Johnson's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Johnson Johnson's value and its price as these two are different measures arrived at by different means. Investors typically determine if Johnson Johnson is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Johnson Johnson's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.